Award Data

The Bottom Feeder project is designed to prove out the research done in Phase I using a prototype platform. The prototype will be a full size version of the platform designed during Phase I. The Phase I platform was designed to work in two operational configurations, a highly efficient mode and a highly maneuverable mode, with the ability to switch between them while submerged. The platform is equ ...

Oncology drugs continue to advance at a rapid pace with many therapies delivered orally as tablets or capsulesSmaller childrenhowevercannot swallow tablets or capsulesFor these drugs to be used in the pediatric population they need to be reformulatedTraditionally this has meant creating a liquid suspensionchewableor rapid dissolve tabletCancer medicationshoweveroften have terrible taste profiles t ...

This application describes the commercialization of the Geodesic Transcranial Electrical Neuromodulation (GTEN) technology to achieve noninvasive neuromodulation with improved spatiotemporal precision. The GTEN system enables both EEG source analysis and configurable electrical neuromodulation with the 256 electrodes of the Geodesic Sensor Net. Now in beta release to selected research customers, t ...

Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

Abstract The Specific Aim of this Phase IIb (Phase II competitive renewal) SBIR proposal is to advance the prototypes we developed under our Phase I and II SBIR grants into commercial production. We will produce SBS-96 format radiation sterilizable electronically tagged sample vials that can be read at ultra-low temperatures. Hundreds of millions of SBS-96 vials are sold each year and each of thes ...

Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...

PROJECT SUMMARY/ABSTRACT The most significant advance in the treatment of Myocardial Infarction (MI) has been reperfusion therapy, which must be applied immediately after the MI diagnosis has been made. Despite the thousands of studies on drug therapies designed to reduce the size of the MI, most have failed in clinical trials. Our hypothesis is that a major reason why these drugs failed is that t ...

PROJECT SUMMARY The goal of this project is to complete the preclinical development of Elex Biotechandapos;s novel compounds that target and treat the underlying molecular cause of catecholaminergic polymorphic ventricular tachycardia (CPVT) CPVT. There are no FDA-approved treatments for CPVT, a rare genetic disorder affecting 1/10,000 individuals, with typical onset in children 7-9 years of age a ...

The goal of this project is to develop novel technology for predicting drug-induced kidney injury such as caused by systemic antimicrobials, diuretics, anticancer agents, and anti-inflammatory drugs. Drugs cause approximately 20 percent of community- and hospital- acquired episodes of acute renal failure, but the incidence in older adults may be as high as 60 percent. A significant problem is that ...

While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...